← Back to Search

Alio Smart Patch Monitoring for Cancer Patients

N/A

Waitlist Available

Led By Naji Mallat, MD

Research Sponsored by Case Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants who are 18 years of age or older

Expected chemotherapy treatment duration of at least 12 weeks

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 13 weeks from entering study

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to reduce the risks and side effects of cancer treatment by continuously monitoring vital signs and blood levels using a wireless device called Alio Smartpatch™. Participants will also use continuous glucose monitors to

Who is the study for?

This trial is for cancer patients at risk of febrile neutropenia, a condition with fever and low white blood cell count after chemotherapy. Participants should be willing to wear the Alio Smart Patch™ for continuous monitoring of vital signs and blood levels.

What is being tested?

The study tests if using the Alio Smart Patch™ can help detect and treat side effects from chemotherapy earlier by continuously monitoring vital signs and blood levels, including glucose, with remote supervision by Quantify Remote Care.

What are the potential side effects?

While not directly related to treatment, wearing the Alio Smart Patch™ may cause skin irritation or discomfort. The intervention aims to monitor health status rather than produce direct side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I am expected to undergo chemotherapy for at least 12 weeks.

Select...

I have been diagnosed with either soft tissue sarcoma, lung, head and neck, breast, pancreatic cancer, or melanoma.

Select...

I am starting a chemotherapy with a high risk of severe infection due to low white blood cell count.

Select...

I am starting on immunotherapy alone or with chemotherapy for my treatment.

Select...

I can read and/or speak English.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 13 weeks from entering study

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 13 weeks from entering study

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 13 weeks from entering study for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Participant compliance

Secondary study objectives

Clinical effectiveness of the integrated QRC ECM and smartpatch as measured by early detection

Clinical effectiveness of the integrated QRC ECM and smartpatch as measured by frequency of emergency care

Identification of febrile neutropenia symptoms

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Remote Monitoring with SmartpatchExperimental Treatment1 Intervention

Participants will be continuously monitored through the device, providing crucial physiological data. The Smartpatch will allow for early detection of chemotherapy-related toxicities.

0 / 6Eligibility criteria met